Inovio Pharmaceuticals vs Serina Therapeutics
Inovio Pharmaceuticals reported revenue of $0 million in fiscal 2025, about the same as Serina Therapeutics' $0 million in fiscal 2025. Inovio Pharmaceuticals' revenue fell 70.0% in its latest year, and Serina Therapeutics' grew 132.1%. Inovio Pharmaceuticals had an operating margin of -132871.3%, against -18478.5% at Serina Therapeutics. Free cash flow was −$89 million at Inovio Pharmaceuticals and −$18 million at Serina Therapeutics.
Side by side
| Inovio Pharmaceuticals | Serina Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $0M | $0M |
| Revenue growth | −70.0% | 132.1% |
| Revenue growth a year, last 5 years | −57.7% | −24.2% |
| Gross margin | — | — |
| Operating margin | −132,871.3% | −18,478.5% |
| Net margin | −130,000.0% | −14,755.4% |
| Free cash flow | −$89M | −$18M |
| Free cash flow margin | −136,074.5% | −13,856.9% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 72.6% | 38.5% |
| Last close | $1.71 | $1.20 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | bought $77,955, sold $335,128 |
| Piotroski F-score | 0 of 8 | 2 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Inovio PharmaceuticalsSerina Therapeutics
Operating margin
Percent of revenue
Inovio PharmaceuticalsSerina Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Inovio PharmaceuticalsSerina Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Inovio Pharmaceuticals and Serina Therapeutics pages.